Albumin replacement therapy targeting serum levels ≥ 3.0 g/dL does not improve 90-day survival in patients with septic shock in the emergency department, a trial shows.

Neoadjuvant chemoimmunotherapy may beat immunotherapy alone when it comes to pathologic response, but its impact on survival remains to be seen.

A new Cleveland Clinic study of nearly 8,000 patients found that people who stop popular GLP-1 weight-loss drugs often avoid ...

Tirzepatide, which is marketed as Zepbound for chronic weight management, is a dual GIP and GLP-1 receptor agonist that has ...

Virta Health, the leader in reversing metabolic disease, announced today results from a randomized, controlled Phase II clinical trial (RCT), offering an early signal that could reshape how advanced ...

A once-daily pill called sulthiame cut breathing interruptions during sleep by up to 47 percent in adults with obstructive sleep apnea, according to a completed phase 2 clinical trial conducted across ...

Appropriate use of immune checkpoint inhibitors and immunotherapy differs in adults with unresectable, metastatic cutaneous ...

By Ahmed Aboulenein and Julie Steenhuysen WASHINGTON, March 10 (Reuters) - The U.S. FDA on Tuesday approved leucovorin, a ...

High-dose Vitamin D doesn't reduce acute COVID severity but shows a promising signal for reducing Long COVID and brain fog.

Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on ...

After the FDA’s first-ever public listening meeting on data-sharing in the cell and gene therapy space, new draft guidance aims to standardize the practice. But recent decisions call into question ...

FDA granted a narrow indication for CFD-FOLR1, targeting impaired folate transport into the CNS that drives developmental delay, seizures, movement disorders, and autistic features in some patients.